ES2560012T3 - Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias - Google Patents

Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias Download PDF

Info

Publication number
ES2560012T3
ES2560012T3 ES12719752.3T ES12719752T ES2560012T3 ES 2560012 T3 ES2560012 T3 ES 2560012T3 ES 12719752 T ES12719752 T ES 12719752T ES 2560012 T3 ES2560012 T3 ES 2560012T3
Authority
ES
Spain
Prior art keywords
seq
promoter
amino acid
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12719752.3T
Other languages
English (en)
Spanish (es)
Inventor
Olivier Vittecoq
Céline DERAMBURE
Thierry Lequerre
Olivier Boyer
François TRON
Xavier Le Loet
Danièle GILBERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rouen
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Rouen
Original Assignee
Universite de Rouen
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Rouen, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Rouen filed Critical Universite de Rouen
Application granted granted Critical
Publication of ES2560012T3 publication Critical patent/ES2560012T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES12719752.3T 2011-05-10 2012-05-10 Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias Active ES2560012T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305557 2011-05-10
EP11305557 2011-05-10
PCT/EP2012/058678 WO2012152882A1 (en) 2011-05-10 2012-05-10 Methods and pharmaceutical compositions for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ES2560012T3 true ES2560012T3 (es) 2016-02-17

Family

ID=44653630

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12719752.3T Active ES2560012T3 (es) 2011-05-10 2012-05-10 Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias

Country Status (5)

Country Link
US (1) US20140086895A1 (US20090208454A1-20090820-C00047.png)
EP (1) EP2707018B1 (US20090208454A1-20090820-C00047.png)
JP (1) JP2014517832A (US20090208454A1-20090820-C00047.png)
ES (1) ES2560012T3 (US20090208454A1-20090820-C00047.png)
WO (1) WO2012152882A1 (US20090208454A1-20090820-C00047.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment
EA201691420A1 (ru) 2014-01-13 2016-12-30 Берг Ллк Композиции енолазы 1 (eno1) и их применение
CN107847560A (zh) * 2015-06-22 2018-03-27 博格有限责任公司 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途
CA3195040A1 (en) * 2020-10-06 2022-04-14 Matthias W. Hentze Screening method for the identification of novel therapeutic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929758A (en) 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US4102877A (en) 1976-07-28 1978-07-25 Merck & Co., Inc. Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US20100047256A1 (en) * 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
NZ595310A (en) * 2009-03-30 2013-05-31 Nestec Sa Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis; vimentin fragments
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment

Also Published As

Publication number Publication date
JP2014517832A (ja) 2014-07-24
EP2707018B1 (en) 2015-11-04
US20140086895A1 (en) 2014-03-27
EP2707018A1 (en) 2014-03-19
WO2012152882A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
Descombes et al. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the sam mRNA
JP2020506701A (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
ES2560012T3 (es) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
US10729789B2 (en) Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
Soininen et al. The mouse Enhancer trap locus 1 (Etl-1): a novel mammalian gene related to Drosophila and yeast transcriptional regulator genes
US10259850B2 (en) Modified DKK2 protein, nucleic acid encoding the same, preparation method thereof, and use thereof
Goodson et al. Prdm1 overexpression causes a photoreceptor fate-shift in nascent, but not mature, bipolar cells
US20100081789A1 (en) Novel Vectors for Production of Interferon
Ricquier et al. The biochemistry of white and brown adipocytes analysed from a selection of proteins
US11739129B2 (en) AP4 and methods of promoting T cell activation
KR102610068B1 (ko) 새로운 재생 치료제로서의 camkk1
US20210275639A1 (en) Compositions for the treatment of sarcopenia or disuse atrophy
KR20070007894A (ko) 항비만약
JP5158785B2 (ja) 生物時計を調節するタンパク質及びその遺伝子
US9783783B2 (en) Compositions and methods for the expansion of stem cells
CN110904046A (zh) Islr基因在制备治疗肥胖及改善胰岛素抵抗的药物中的应用
TWI356098B (en) Promoter of secreted protein acidic and rich in cy
Rajesh et al. The growth hormone-encoding gene isolated and characterized from Labeo rohita Hamilton is expressed in CHO cells under the control of constitutive promoters in ‘autotransgene’constructs
JPWO2009013794A1 (ja) インスリン分泌誘導剤及び膵臓β細胞増加促進剤
KR101411296B1 (ko) 지방체 이동 신호 펩타이드 및 이를 이용하여 이종단백질을 지방체로 이동시키는 방법
RU2557385C1 (ru) Кодон-оптимизированные последовательности и фармацевтическая композиция для восстановления кровеносных сосудов
XU et al. Expression and function of embryonic skeletal muscle development of leizhou black duck
CA3154463A1 (en) Vasculogenic fibroblasts
US20090035300A1 (en) Immunomodulation of dendritic cells
Ozturk Identification of cis-elements and trans-acting factors that are involved in rat placental lactogen II (rPLII) gene expression in placenta